Correction of myopic astigmatism

Article

A study on the Artiflex toric phakic IOL

Over the past few decades, several designs have been developed, including angle-supported anterior chamber pIOLs, posterior chamber pIOLs and iris-fixated pIOLs. In 1978 Jan Worst designed the iris-claw IOL, a coplanar single-piece PMMA IOL that was enclavated in a fold of midperipheral iris stroma, a relatively immobile portion of the iris. Several versions of the lens are available: The Artisan pIOL for correction of myopia (6 mm optic), hyperopia and astigmatism (5 mm optic), and a flexible version (Artiflex for the correction of myopia). These lenses are also distributed under the label Verisyse and Veriflex by AMO (Abbott Medical Optics, Illinois, USA).

The toric Artiflex

Additionally, the toric Artiflex lenses are available with a 0° or a 90° cylinder. In eyes with a preoperative cylinder axis between 0 and 45 degrees or between 135 and 180 degrees, an IOL with a torus at 0 degrees is recommended. In eyes with a preoperative cylinder axis between 45 and 135 degrees, a torus at 90 degrees is recommended. This enables implantation of the pIOL in a horizontal or slightly oblique position through a 12 o'clock incision, as well as in a more or less vertical position through a temporal incision.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.